HKEX Filings
- 
					Oct 28, 2022
RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE
 - 
					Oct 14, 2022
TERMINATION OF DISCLOSABLE TRANSACTION IN RELATION TO THE LEASE AGREEMENT
 - 
					Oct 9, 2022
INSIDE INFORMATION - CLOVER PROVIDES UPDATE ON 2022 CORPORATE MILESTONES
 - 
					Oct 5, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2022
 - 
					Sep 20, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE RECEIVES EU GMP CERTIFICATE
 - 
					Sep 20, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S UNIVERSAL COVID-19 BOOSTER VACCINE CANDIDATE DEMONSTRATES SUPERIOR NEUTRALIZATION OF OMICORN BA.5 COMPARED TO INACTIVATED VACCINE
 - 
					Sep 16, 2022
Notification Letter and Request Form for Non-Registered Shareholders
 - 
					Sep 16, 2022
2022 Interim Report
 - 
					Sep 15, 2022
VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE ADVANCE PURCHASE AGREEMENT
 - 
					Sep 6, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES SUPERIOR BOOSTER RESPONSES COMPARED TO INACTIVATED VACCINE
 - 
					Sep 2, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month ended August 31, 2022
 - 
					Aug 30, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 BOOSTER VACCINE CANDIDATE DEMONSTRATES ROBUST NEUTRALIZATION OF DOMINANT OMICRON BA.5 SUBVARIANT
 - 
					Aug 25, 2022
VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE 2/3 RESULTS IN ADOLESCENTS FOR CLOVER'S COVID-19 VACCINE
 - 
					Aug 24, 2022
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
 - 
					Aug 11, 2022
DATE OF BOARD MEETING
 - 
					Aug 4, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month ended July 31, 2022
 - 
					Jul 19, 2022
GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
 - 
					Jul 4, 2022
Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2022
 - 
					Jun 27, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES STRONG CROSS-NEUTRALIZATION AGAINST OMICRON AS A HOMOLOGOUS BOOSTER
 - 
					Jun 20, 2022
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
 



